Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Normand Beaulieu, Isabelle Dupont, Claire Bonfils, Marja Dubay, Hélène Ste-Croix, Lubo Isakovic, Stephen Claridge, Oscar Saavedra, Franck Raeppel, Stephane Raeppel, Michael Mannion, Arkadii Vaisburg, Jeffrey M. Besterman and Christiane R. Maroun | ||||||||||||
Title | Abstract 3609: MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met mutants | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/70/8_Supplement/3609.short | ||||||||||||
Abstract Text | AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3609 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|